CervoMed Inc. (CRVO) - Total Liabilities
Based on the latest financial reports, CervoMed Inc. (CRVO) has total liabilities worth $4.50 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of CervoMed Inc. to track the company's year-over-year net asset growth rate.
CervoMed Inc. - Total Liabilities Trend (1998–2025)
This chart illustrates how CervoMed Inc.'s total liabilities have evolved over time, based on quarterly financial data. See CRVO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CervoMed Inc. Competitors by Total Liabilities
The table below lists competitors of CervoMed Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Investors House
HE:INVEST
|
Finland | €18.01 Million |
|
Medhelp Care AB
ST:MEDHLP
|
Sweden | Skr28.58 Million |
|
Skin n Skin Co. Ltd
KQ:159910
|
Korea | ₩22.30 Billion |
|
Synergy House Berhad
KLSE:0279
|
Malaysia | RM147.39 Million |
|
New Bubbleroom Sweden AB
ST:BBROOM
|
Sweden | Skr105.25 Million |
|
PLB Engineering Bhd
KLSE:7055
|
Malaysia | RM164.12 Million |
|
Petratherm Ltd
AU:PTR
|
Australia | AU$466.42K |
|
Ugint Co Ltd
KQ:195990
|
Korea | ₩22.30 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down CervoMed Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CervoMed Inc. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CervoMed Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CervoMed Inc. (1998–2025)
The table below shows the annual total liabilities of CervoMed Inc. from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.18 Million | +33.44% |
| 2024-12-31 | $3.88 Million | +49.45% |
| 2023-12-31 | $2.60 Million | -80.27% |
| 2022-12-31 | $13.16 Million | +349.35% |
| 2021-12-31 | $2.93 Million | +0.42% |
| 2020-12-31 | $2.92 Million | -29.65% |
| 2019-12-31 | $4.14 Million | +59.98% |
| 2018-12-31 | $2.59 Million | -47.30% |
| 2017-12-31 | $4.92 Million | -40.77% |
| 2016-12-31 | $8.30 Million | +258.02% |
| 2015-12-31 | $2.32 Million | -49.75% |
| 2014-12-31 | $4.61 Million | -61.17% |
| 2013-12-31 | $11.88 Million | -43.03% |
| 2012-12-31 | $20.85 Million | +5.99% |
| 2011-12-31 | $19.68 Million | +254.17% |
| 2010-12-31 | $5.56 Million | +46.60% |
| 2009-12-31 | $3.79 Million | -23.03% |
| 2008-12-31 | $4.92 Million | -35.30% |
| 2007-12-31 | $7.61 Million | +5222.53% |
| 2006-12-31 | $142.96K | +50.70% |
| 2005-12-31 | $94.86K | -99.51% |
| 1999-12-31 | $19.41 Million | +49.31% |
| 1998-12-31 | $13.00 Million | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more